{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:37:55Z","timestamp":1787315875871,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug discovery and development is commonly schematized as a \u201cpipeline,\u201d and, although appreciated by drug developers to be a useful oversimplification, this cartology may perpetuate inaccurate notions of straightforwardness and is of minimal utility for process engineering to improve efficiency. To create a more granular schema, a group of drug developers, researchers, patient advocates, and regulators developed a crowdsourced atlas of the steps involved in translating basic discoveries into health interventions, annotated with the steps that are particularly prone to difficulty or failure. This Drug Discovery, Development, and Deployment Map (4DM), provides a network view of the process, which will be useful for communication and education to those new to the field, orientation and navigation of individual projects, and prioritization of technology development and re\u2010engineering endeavors to improve efficiency and effectiveness. The 4DM is freely available for utilization, modification, and further development by stakeholders across the translational ecosystem.<\/jats:p>","DOI":"10.1111\/cts.12531","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T03:07:54Z","timestamp":1514084874000},"page":"166-174","source":"Crossref","is-referenced-by-count":29,"title":["Application of a Dynamic Map for Learning, Communicating, Navigating, and Improving Therapeutic Development"],"prefix":"10.1111","volume":"11","author":[{"given":"John A.","family":"Wagner","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals International Co.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Dahlem","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn D.","family":"Hudson","sequence":"additional","affiliation":[{"name":"Critical Path Institute  Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon F.","family":"Terry","sequence":"additional","affiliation":[{"name":"Genetic Alliance  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russ B.","family":"Altman","sequence":"additional","affiliation":[{"name":"Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Taylor","family":"Gilliland","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"DeFeo","sequence":"additional","affiliation":[{"name":"Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Austin","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003505"},{"key":"e_1_2_8_2_1","unstructured":"Navigating the Ecosystem of Translational Science.http:\/\/www.geneticalliance.org\/programs\/biotrust\/nets\/fullview."},{"key":"e_1_2_8_3_1","unstructured":"The Drug Development Process.https:\/\/www.fda.gov\/ForPatients\/Approvals\/Drugs\/default.htm."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1131"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.217"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60601-1"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.04.044"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.02.011"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.01.003"},{"key":"e_1_2_8_10_1","unstructured":"Food and Drug Administration. Qualification of biomarker\u2014total kidney volume in studies for treatment of autosomal dominant polycystic kidney disease guidance for industry.https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM458483.pdf(2016)."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2007.54"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.12"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.06.052"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1346.008"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.05.013"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1888"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.08.002"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.02.098"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1039\/c0ob00631a"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.03.011"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:13:59Z","timestamp":1695532439000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/cts.12531"],"URL":"https:\/\/doi.org\/10.1111\/cts.12531","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,22]]}}}